⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for myelodysplastic

Every month we try and update this database with for myelodysplastic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)NCT00854646
Acute Myelocyti...
Acute Lymphocyt...
Chronic Myelocy...
Chronic Lymphoc...
Myelodysplastic...
ON 01910.Na
18 Years - Traws Pharma, Inc.
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)NCT00854646
Acute Myelocyti...
Acute Lymphocyt...
Chronic Myelocy...
Chronic Lymphoc...
Myelodysplastic...
ON 01910.Na
18 Years - Traws Pharma, Inc.
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDSNCT04810611
Myelodysplastic...
MBG453
NIS793
canakinumab
18 Years - Novartis
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)NCT00867061
Myelodysplastic...
ON 01910.Na Con...
18 Years - Traws Pharma, Inc.
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)NCT03016130
Leukemia
Myelodysplastic...
Diet
18 Years - University of Florida
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)NCT00854646
Acute Myelocyti...
Acute Lymphocyt...
Chronic Myelocy...
Chronic Lymphoc...
Myelodysplastic...
ON 01910.Na
18 Years - Traws Pharma, Inc.
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.NCT01236144
Acute Myeloid L...
High Risk Myelo...
Plerixafor
AC220
Ganetespib
60 Years - Cardiff University
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.NCT01236144
Acute Myeloid L...
High Risk Myelo...
Plerixafor
AC220
Ganetespib
60 Years - Cardiff University
Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)NCT03016130
Leukemia
Myelodysplastic...
Diet
18 Years - University of Florida
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: